What Drugs Are Downers? Types, Effects, and Risks

“Downers” is the street term for central nervous system (CNS) depressants, a broad class of drugs that slow brain activity, reduce alertness, and relax the body. The category includes some of the most widely prescribed medications on the planet, from benzodiazepines like Xanax and Valium to opioid painkillers like oxycodone, as well as alcohol, barbiturates, and lesser-known substances like GHB. Roughly 3% to 7% of the U.S. population uses a prescribed CNS depressant at any given time, which makes understanding the risks more than an academic exercise.¹

The Main Categories of Downers

The term “downer” covers a surprisingly varied set of substances. What unites them is their net effect on the brain: they dampen neural signaling, producing some combination of sedation, anxiety relief, pain reduction, and muscle relaxation. The differences lie in which receptors they target and how aggressively they do it.

Benzodiazepines: Drugs like diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan), and clonazepam (Klonopin). Prescribed for anxiety, insomnia, seizures, and muscle spasms. Between 1996 and 2014 the number of U.S. adults filling prescriptions for benzodiazepine-site drugs rose from about 8.1 million to 13.5 million, and overdose deaths involving these drugs quadrupled over the same period.²
Opioids: Prescription painkillers (hydrocodone, oxycodone, morphine, fentanyl) and illicit drugs like heroin. They primarily target mu-opioid receptors, producing pain relief and euphoria alongside sedation.
Barbiturates: Older sedatives like phenobarbital and secobarbital. Once the go-to sleeping pill, they fell out of favor due to a narrow margin between an effective dose and a lethal one. Today they survive mainly in anesthesia and certain epilepsy treatments.³
Z-drugs: Zolpidem (Ambien), zaleplon, and eszopiclone. Designed as supposedly safer alternatives to benzodiazepines for insomnia, they act on similar receptor sites and carry similar risks of misuse.²
Alcohol: The most widely used CNS depressant worldwide. It affects multiple receptor systems simultaneously, including the same GABA pathway that benzodiazepines act on.
GHB: Gamma-hydroxybutyric acid, sometimes called “liquid ecstasy” despite being a depressant, not a stimulant. It produces euphoria at low doses but sedation, amnesia, and even coma at higher ones.⁴

A few other substances straddle the boundary. Muscle relaxants like tizanidine and cyclobenzaprine have sedating properties. First-generation antihistamines like diphenhydramine (Benadryl) cross the blood-brain barrier and cause drowsiness, which is why they are sometimes misused as sleep aids. And gabapentinoids (gabapentin and pregabalin), originally developed for seizures and nerve pain, have increasingly been used recreationally for their calming, mildly euphoric effects.

How These Drugs Slow the Brain Down

Most downers converge on one of two main strategies for quieting neural activity. The first involves boosting a brain chemical called GABA, which is the nervous system’s primary brake signal. Benzodiazepines, barbiturates, Z-drugs, alcohol, and GHB all increase GABA’s ability to slow neuron firing, though they do it at slightly different spots on the receptor and with different intensities. Barbiturates, for instance, can directly open the GABA receptor’s chloride channel at high doses, which is one reason their overdose potential is so much higher than that of benzodiazepines. GHB’s depressant effects at recreational doses are also mostly routed through GABA-B receptors rather than its own dedicated receptor.⁴

Opioids take a different path. Instead of amplifying the brake signal, they activate mu-opioid receptors in brain regions involved in pain processing, reward, and, critically, breathing. Sedation is one of the most common side effects, and researchers have been working to understand exactly how opioids produce it, since the mechanism is not as simple as just “turning down” the brain.⁵ What makes opioids dangerous is not so much their sedating quality but their effect on the brainstem’s breathing centers, something covered more below.

Alcohol is uniquely messy pharmacologically. It enhances GABA activity, but it also interferes with a different receptor system called NMDA, which is involved in excitatory signaling, learning, and memory formation. Research in animal models has shown that ethanol inhibits NMDA receptor function and the long-term potentiation processes the brain uses to encode new memories, which helps explain why heavy drinking causes blackouts.⁶

Respiratory Depression and the Overdose Risk

The most immediate life-threatening danger of downers is respiratory depression: they slow breathing to the point where the body cannot take in enough oxygen. This is the primary mechanism of death in overdoses involving opioids, barbiturates, and high-dose benzodiazepines or alcohol.

With opioids, the effect is well mapped. Mu-opioid receptors sit in a brainstem area called the pre-Bötzinger complex, which acts as the brain’s breathing pacemaker, and in a nearby region called the parabrachial/Kölliker-Fuse nuclei. Animal research has demonstrated that when opioid receptors are genetically removed from both of these sites, morphine barely affects breathing at all, suggesting these two small clusters of neurons are together responsible for opioid-induced respiratory depression.⁷ This finding matters because it tells researchers where to look when designing safer painkillers, but for the average person, the takeaway is straightforward: opioids don’t just make you drowsy, they suppress the automatic drive to breathe.⁸

Benzodiazepines alone are less likely to cause fatal respiratory depression than opioids or barbiturates, which is partly why they replaced barbiturates as the preferred anxiety and sleep medication. But “less likely” is not the same as “safe,” especially when benzodiazepines are combined with another depressant.

Why Mixing Downers Is So Dangerous

Combining two or more depressants doesn’t just add their effects together; the interaction can multiply the risk. Alcohol and sedative-hypnotics both boost GABA transmission, and using them together produces stronger sedation and greater cognitive impairment than either alone.¹ Alcohol combined with prescription opioids like hydrocodone or oxycodone raises the risk of fatal respiratory depression through synergistic effects on both mu-opioid and GABA receptor pathways.¹

The opioid-plus-benzodiazepine combination has received particular scrutiny. Patients with chronic pain who use opioids along with benzodiazepines or alcohol are at higher risk for both fatal and nonfatal overdose and tend to show more problematic drug-taking behaviors overall.⁹ This is not a niche problem; many people who have a legitimate prescription for one depressant also use another, whether prescribed or not. The FDA added boxed warnings to both opioid and benzodiazepine labels years ago flagging this combination, but the practice remains common.

What makes poly-depressant overdose especially tricky is that a person may be tolerant to one substance but not the other. Someone who takes a benzodiazepine daily for anxiety might feel comfortable adding a few drinks, not realizing that the alcohol-benzodiazepine interaction creates a level of respiratory suppression their body has never encountered.

Tolerance, Dependence, and Withdrawal

One of the defining features of downers is how readily the brain adapts to their presence. With repeated exposure, the brain recalibrates by reducing the sensitivity or number of its GABA receptors, a process sometimes called down-regulation. Laboratory studies have shown that chronic GABA exposure leads to reduced receptor binding and diminished chloride-channel function in cortical neurons, essentially weakening the brain’s response to its own calming signals.¹⁰ Chronic alcohol exposure produces a related but distinct change: the receptor sites still exist in roughly the same number, but the coupling between them becomes uncoupled by around 40%, meaning GABA’s ability to enhance sedation at the receptor level drops sharply.¹¹

This tolerance is the first step in a cycle that leads to dependence. You need more of the drug to feel the same effect, and when you stop taking it, the brain’s dampened baseline leaves it in a state of overexcitement. Withdrawal from alcohol and benzodiazepines can be medically dangerous, potentially involving seizures and, in severe cases, delirium. Opioid withdrawal, while intensely unpleasant, is less commonly life-threatening and very rarely involves delirium.¹² The difference reflects the underlying biology: alcohol and benzodiazepines suppress the brain’s excitatory activity so broadly that removing them can trigger a rebound seizure, whereas opioid withdrawal primarily produces autonomic symptoms like sweating, cramping, and rapid heart rate.

The practical implication is that stopping a benzodiazepine or heavy alcohol habit abruptly can be genuinely life-threatening and should always be done under medical supervision with a gradual taper. Opioid withdrawal, while brutally uncomfortable, is better managed with medications like buprenorphine that ease symptoms without the same risk of seizures.

Long-Term Cognitive Effects of Benzodiazepines

Beyond the immediate risks of overdose and dependence, research has raised alarms about what prolonged benzodiazepine use does to the brain over years. A meta-analysis of observational studies found that long-term benzodiazepine users had a roughly 21% higher risk of developing dementia compared to short-term users.¹³ That association alone does not prove causation, since people who develop dementia often experience anxiety and insomnia in the years before diagnosis, meaning they may be prescribed benzodiazepines because of early, unrecognized disease.

However, laboratory work is filling in a plausible biological mechanism. A study in mice found that long-term diazepam treatment impaired the structural plasticity of dendritic spines, the tiny protrusions on neurons where synaptic connections are made, and that this damage was linked to cognitive impairment.¹⁴ Experimental models have also shown that weeks of benzodiazepine exposure can blunt neuroplasticity, making synapses less stable and reducing the dendritic spines that support formation of new connections. These changes could leave memory circuits less adaptable over time.¹⁵

The honest state of the science is that we cannot yet cleanly separate the drug’s direct effects from the confounding fact that many benzodiazepine users already have risk factors for cognitive decline. But the accumulating biological evidence means it is reasonable to be cautious about years-long benzodiazepine use, especially in older adults.

Falls and Fractures in Older Adults

For people over 65, downers carry a risk that goes beyond the brain: falling. Sedation, slowed reflexes, muscle relaxation, and impaired balance all raise the likelihood of falls, and falls in older adults often mean fractures. A cross-sectional study of 200 elderly patients found that those using sedative-hypnotic drugs had a higher rate of fractures (74%) compared to non-users (52%), though the difference in that particular study narrowly missed the conventional threshold for statistical significance.¹⁶ Benzodiazepines were the most commonly used sedative class in that sample. The broader clinical literature consistently identifies sedative-hypnotics as a fall risk factor in geriatric populations, which is why guidelines for prescribing in older adults recommend using the lowest effective dose for the shortest possible time.

Xylazine and the Changing Drug Supply

The landscape of downers is not static. The opioid crisis has evolved through several phases, and the current one is defined by polysubstance use and a drug supply contaminated with novel adulterants. Fentanyl now dominates the illicit opioid supply, and it is frequently mixed with other substances that users may not expect.¹⁷

Xylazine is one of the most concerning new additions. It is a veterinary sedative, not approved for human use, that acts on alpha-2 adrenergic receptors to produce heavy sedation and muscle relaxation. When mixed into fentanyl, xylazine creates a particularly dangerous situation: it deepens and prolongs sedation, but because it does not work through opioid receptors, naloxone (Narcan) only partially reverses the overdose. People exposed to xylazine-laced fentanyl may remain unconscious even after naloxone administration. Xylazine also causes distinctive necrotic skin wounds at and distant from injection sites, a feature that has become a clinical warning sign.¹⁸

Designer benzodiazepines and nitazenes (ultra-potent synthetic opioids) are also appearing in the drug supply with increasing frequency. These substances often do not show up on standard drug tests, and their potency can vary wildly from batch to batch. For anyone who uses drugs recreationally or who works in emergency medicine, the practical takeaway is that “downers” in the current era are rarely a single substance, and the unpredictability of the supply has made overdose prevention harder than ever.

Reversal Drugs and Emergency Response

Two specific antidotes exist for the most common classes of downer overdose. Naloxone (Narcan) is a competitive antagonist at the mu-opioid receptor, meaning it physically displaces opioids from the receptor and reverses their effects, including respiratory depression. Flumazenil does the same for benzodiazepines, blocking their action at GABA-A receptors. Both drugs have rapid onset after injection and are highly specific to their target.¹⁹

In practice, though, the two antidotes are treated very differently. Naloxone is widely used as a first-line response for opioid overdoses and is now available without a prescription in many places. Flumazenil is used much more cautiously and is generally discouraged as a routine treatment for unknown overdoses. The reason is that giving flumazenil to someone physically dependent on benzodiazepines can precipitate seizures, making a bad situation worse. This asymmetry matters: in an emergency, naloxone is relatively safe to administer even without knowing the specific opioid involved, while flumazenil requires more clinical judgment.¹⁹

Neither antidote works against barbiturates, alcohol, GHB, or xylazine. For those substances, treatment is primarily supportive: maintaining an airway, providing mechanical ventilation if needed, and waiting for the drug to clear the body.

GHB and Its Unusual Profile

GHB deserves separate attention because it occupies an unusual space among downers. At low doses it produces euphoria and mild relaxation, which is why it has a reputation as a party drug. At slightly higher doses it becomes a potent sedative, producing deep unconsciousness and short-term amnesia.²⁰ The margin between a dose that produces a pleasant buzz and one that renders someone unconscious is thin, which is the core of its danger.

GHB is actually a naturally occurring substance in the brain, a metabolite of GABA, and it has its own dedicated receptor. But when taken as a drug, the effects people experience, sedation, memory impairment, increased deep sleep, dependence, and at high doses, seizures and coma, are mostly driven by its action on GABA-B receptors rather than its own receptor.⁴ Animal research has also found that GHB treatment alters receptor density in brain regions tied to spatial learning and memory, particularly the hippocampus, suggesting that repeated use could impair cognitive function beyond just the acute high.²⁰

Newer Sleep Drugs That Bypass the Depressant Pathway

The risks associated with GABA-targeting sleep drugs have driven interest in alternatives that promote sleep without globally depressing brain activity. Dual orexin receptor antagonists, or DORAs, represent the most significant departure. These drugs, which include suvorexant (Belsomra) and lemborexant (Dayvigo), work by blocking orexin, a neuropeptide that promotes wakefulness, rather than by amplifying the brain’s inhibitory signals. The result is a more targeted nudge toward sleep rather than the broad neural suppression caused by benzodiazepines, Z-drugs, and barbiturates.²¹

The appeal of DORAs is that they appear to carry a lower risk of the classic depressant side effects: respiratory depression, rebound insomnia, and abuse potential. Traditional GABA-modulating sleep drugs induce a kind of global brain depression and are linked to substantial side effects that limit long-term use.²¹ DORAs are not perfect, and they can cause next-day drowsiness and unusual dreams, but they represent a meaningful shift in how the field thinks about treating insomnia. For someone currently using a benzodiazepine or Z-drug for sleep and wondering about alternatives, they are worth discussing with a prescriber, especially for long-term use where the cognitive and dependency risks of traditional downers accumulate.

1
PubMed Central. Trends in Prescribed Central Nervous System Depressant Medications Among Adults Who Regularly Consume Alcohol: United States 1999 to 2014
2
Frontiers in Psychiatry. Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond
3
PubMed Central. The history of barbiturates a century after their clinical introduction
4
PubMed Central. Unravelling the brain targets of gamma-hydroxybutyric acid
5
PubMed. Definition of and mechanism for opioid-induced sedation
6
PubMed Central. Alcohol inhibition of the NMDA receptor function, long-term potentiation, and fear learning requires striatal-enriched protein tyrosine phosphatase
7
eLife. Opioids depress breathing through two small brainstem sites
8
PubMed. Non-analgesic effects of opioids: opioid-induced respiratory depression
9
PubMed Central. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use
10
PubMed. Chronic GABA exposure down-regulates GABA-benzodiazepine receptor-ionophore complex in cultured cerebral cortical neurons
11
PubMed. Effects of chronic ethanol exposure on the gaba-benzodiazepine receptor complex in rat brain
12
PubMed Central. Opioid Withdrawal Presenting as Delirium and Role of Buprenorphine: A Case Series
13
PubMed Central. Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies
14
PubMed. Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18 kDa translocator protein (TSPO)
15
Journal of the Neurological Sciences. Benzodiazepine use and risk of dementia: Disentangling the prodromal period in a population-based cohort
16
PubMed Central. Sedative-hypnotic drug use and risk of falls and fractures in elderly patients: a cross-sectional study
17
Frontiers in Public Health. The evolving epidemiology of opioid use disorder: polysubstance use, drug supply transformation, and policy implications
18
Advancements in Health Research. EMERGING DRUGS OF ABUSE IN THE CHRONIC PAIN POPULATION: A CLINICAL PHARMACOLOGY PERSPECTIVE ON KRATOM, NOVEL SYNTHETIC OPIOIDS, DESIGNER BENZODIAZEPINES, GABAPENTINOIDS, XYLAZINE, AND KETAMINE
19
PubMed Central. Flumazenil, naloxone and the ‘coma cocktail’
20
PubMed. Gamma-hydroxybutyrate induces cognitive deficits and affects GABAB receptors and IGF-1 receptors in male rats
21
PubMed Central. Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis